INTERVIEW: DPx's Jim Mullen delivers the $2.6bn message
This article was originally published in Scrip
Executive Summary
The recent merger of Patheon and DPP makes the company one of the largest outsourcing players in the market. CEO Jim Mullen explains why the company now has to live up to the hype.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.